Status:
ACTIVE_NOT_RECRUITING
Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care
Lead Sponsor:
AbbVie
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
Psoriasis is a chronic inflammatory skin condition that is characterized by symptoms such as pain, itching and discomfort. This can have severe impact on the quality of life including depression, emba...
Eligibility Criteria
Inclusion
- Clinical diagnosis of moderate to severe psoriasis.
- Prescribed risankizumab as the standard treatment for psoriasis, according to the local label. The decision to prescribe risankizumab will be made solely by the physician, based on his clinical judgment, and is done prior to any decision to approach the participant to participate in this study.
- Willing to be involved in the study, to sign an informed consent form and complete study questionnaires.
- Participants participating in digital component: Pruritus Numeric Rating Scale (PNRS) score \>=4 at baseline.
Exclusion
- Participants participating in a concurrent clinical interventional study or within 30 days.
- Participants treated with risankizumab prior to baseline visit.
Key Trial Info
Start Date :
April 26 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2026
Estimated Enrollment :
141 Patients enrolled
Trial Details
Trial ID
NCT04780516
Start Date
April 26 2021
End Date
December 1 2026
Last Update
August 13 2025
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Duplicate_Kaplan Medical Center /ID# 226569
Rehovot, Central District, Israel, 7661041
2
Leumit /ID# 252029
Rehovot, Central District, Israel, 9458414
3
HaEmek Medical Center /ID# 251040
Afula, Haifa District, Israel, 1834111
4
Shaare Zedek Medical Center /ID# 247319
Jerusalem, Jerusalem, Israel, 91031